A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 667-670

  Finek, Jindrich ^a   Holubec Jr , Lubos ^a   Svoboda, Tomas ^a   Sefrhansova, Lucie ^a   Pavlikova, Ivana ^a   Votavova, Marie ^a   Sediva, Marcela ^b   Filip, Stanislav ^c   Kozevnikova, Renata ^d   Kormunda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d CZE   (Netherlands)

Author keywords

Capecitabine; Metastatic breast cancer; Oral chemotherapy; Oral vinorelbine; Phase II study

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; VINBLASTINE;

EID: 61449209114     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Briest S and Stearns V: Chemotherapeutic strategies for advanced breast cancer. Oncology 21(11): 1325-1335, 2007.
2. Newman LA, Hayes D: Evidence-based management of breast cancer. In: Oncology. An Evidence-based Approach. 2nd ed., Chang AE (ed.). Springer US, pp. 951-983, 2006.
3. Dieras V, Extra JM, Bellissant M et al: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14(12): 3097-3104, 1996.
4. Berutti A, Sperone P, Bottini A et al: Phase II study of vinorelbine with protracted fluorouracil infusion as second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18(19): 3370-3377, 2000.
5. Eniu A, Vitoc C, Todor N et al: Efficacy and safety data of an outpatient regimen for pretreated metastatic or relapsed breast cancer: vinorelbine, 5-fluorouracil and folinic acid (FuFolNav): a phase II study. Eur J Cancer 3(suppl 2): 131, 2004.
6. Findlay M, Von Minckwitz G, Wardley A et al: Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 19(2): 212-222, 2008.
7. Liu G, Franssen E, Fitch M et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1): 110-115, 1997.
8. Delcambre C, Veyret C, Levy C et al: A phase I/II study of capecitabine combined with oral vinorelbine as first or second line therapy in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 94: S67, 2005.
9. Lorusso V, Spada M, Giampaglia M et al: Oral vinorelbine plus capecitabine combination in patients with advanced breast cancer. A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Annals Oncol 17(Suppl 7): vii 15-17, 2006.
10. Nole F, Catania C, Sanna G et al: Phase II study of an all-oral regimen combining oral vinorelbine with capecitabine as first-line chemotherapy of metastatic breast cancer. Eur J Cancer 5(4): 218, 2007.
11. Tubiana-Mathieu N, Bougnoux P, Becquart D et al: All-oral Vinorelbine and capecitabine combination for chemotherapy-naïve HER2-negative metastatic breast cancer patients: efficacy and safety in an international phase II study. Eur J Cancer 6(7): 173, 2008.
12. Czech Oncological Sosiety CLS JEP: Principle of Cytostatic Treatment of Malignant Diseases Updated. 6th ed., Brno, 2008.